The Latest Breaking News from Dermatology

On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

French drugmaker Sanofi SA (NASDAQ:SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Arcutis Biotherapeutics has a lofty goal for 2025 — and it could help Arcutis stock continue a massive run that helped shares quadruple last year.

In today’s fast-paced healthcare world, few leaders balance clinical expertise and strategic innovation as seamlessly as Dr. Clara Latorre.

Applications for MD dermatology programs have increased 15% in two years in the U.S.

We know retinol increases skin's sensitivity to the sun, so should you leave it behind for a hot holiday?

From dermatology-trained pharmacists to new skin scans and LED light therapy

Learn about the bathing debate sparked by a mom of six on TikTok. Discover the American Academy of Dermatology's guidelines for children's bathing frequency.

Nourish your skin and improve its elasticity over time